Vivoryon Therapeutics N.V. (ENXTAM: VVY)
Health Care · Biotechnology · DE
€0.99
-5.71% today · -39.6% 1Y
Vivoryon Therapeutics N.V. (ENXTAM: VVY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $32.98M and employs 13 people.
Over the last twelve months the share price has lost 39.6%, trading between 0.96 and 1.68.
Tweenvest scores Vivoryon Therapeutics N.V. across four factors: quality 38/100, value 47/100. Its strongest factor is value.
VVY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $32.98M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.24
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- €1.68
- 52-week low
- €0.96
- Avg volume (3M)
- —
- Shares outstanding
- 29.61M
- Employees
- 13
- Next earnings
- —
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
- ISIN
- NL00150002Q7
- Founded
- 1997
- Listed since
- Oct 27, 2014
- Exchange
- Euronext Amsterdam
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CervoMed Inc.NasdaqCM: CRVO | $33.87M | $2.24 | -30.43% |
| Cell Source, Inc.OTCPK: CLCS | $33.63M | $0.49 | -10.45% |
| Mabion S.A.WSE: MAB | $33.59M | zł8.07 | +0.88% |
| Genetics Generation Advancement Corp.TPEX: 4160 | $33.50M | NT$38.80 | -0.26% |
| QuantaMatrix Inc.KOSDAQ: A317690 | $32.77M | ₩2,170.00 | -6.26% |
| Kringle Pharma, Inc.TSE: 4884 | $32.60M | ¥614.00 | -4.81% |
| Quince Therapeutics, Inc.NasdaqGS: QNCX | $32.58M | $32.03 | +0.95% |
| GeneBioTech Co. ,LtdKOSDAQ: A086060 | $32.23M | ₩4,990.00 | -1.58% |
Figures last refreshed Oct 18, 2026.